CL2017001923A1 - Derivados de 9h-pirrolo-dipiridina - Google Patents
Derivados de 9h-pirrolo-dipiridinaInfo
- Publication number
- CL2017001923A1 CL2017001923A1 CL2017001923A CL2017001923A CL2017001923A1 CL 2017001923 A1 CL2017001923 A1 CL 2017001923A1 CL 2017001923 A CL2017001923 A CL 2017001923A CL 2017001923 A CL2017001923 A CL 2017001923A CL 2017001923 A1 CL2017001923 A1 CL 2017001923A1
- Authority
- CL
- Chile
- Prior art keywords
- pyrrolo
- derivatives
- dipyridine
- dipyridine derivatives
- radiopharmactics
- Prior art date
Links
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/041—Heterocyclic compounds
- A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
- A61K51/0463—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Optics & Photonics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15153448 | 2015-02-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2017001923A1 true CL2017001923A1 (es) | 2018-02-16 |
Family
ID=52477553
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2017001923A CL2017001923A1 (es) | 2015-02-02 | 2017-07-27 | Derivados de 9h-pirrolo-dipiridina |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US20180022748A1 (enExample) |
| EP (1) | EP3253762B1 (enExample) |
| JP (1) | JP6579670B2 (enExample) |
| KR (1) | KR102621513B1 (enExample) |
| CN (1) | CN107207508B (enExample) |
| AU (1) | AU2016214537B2 (enExample) |
| BR (1) | BR112017016311A2 (enExample) |
| CA (1) | CA2973648C (enExample) |
| CL (1) | CL2017001923A1 (enExample) |
| DK (1) | DK3253762T3 (enExample) |
| EA (1) | EA036518B1 (enExample) |
| ES (1) | ES2875734T3 (enExample) |
| IL (1) | IL253381B (enExample) |
| MX (1) | MX378155B (enExample) |
| MY (1) | MY191590A (enExample) |
| SG (1) | SG11201705727TA (enExample) |
| WO (1) | WO2016124508A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20110046378A1 (en) | 2008-02-14 | 2011-02-24 | Siemens Medical Solutions Usa, Inc. | Novel Imaging Agents for Detecting Neurological Dysfunction |
| EP3253762B1 (en) * | 2015-02-02 | 2021-05-05 | UCB Biopharma SRL | 9h-pyrrolo-dipyridine derivatives |
| SG11201811311VA (en) * | 2016-07-22 | 2019-01-30 | Ac Immune Sa | Compounds for imaging tau protein aggregates |
| US10865207B2 (en) | 2016-07-22 | 2020-12-15 | Ac Immune S.A. | Compounds for imaging Tau protein aggregates |
| WO2018046428A1 (en) * | 2016-09-09 | 2018-03-15 | F. Hoffmann-La Roche Ag | Process for preparation of 2-(6-nitropyridin-3-yl)-9h-dipyrido[2,3-b;3',4'-d]pyrrole |
| IL304982A (en) * | 2016-11-01 | 2023-10-01 | Arvinas Operations Inc | PROTACS Targeted Tau-Protein and Related Methods of Use |
| EP3636262A4 (en) | 2017-06-02 | 2020-06-10 | FUJIFILM Toyama Chemical Co., Ltd. | AGENT FOR PREVENTING OR TREATING ALZHEIMER-LIKE DEMENTIA |
| KR20220101001A (ko) * | 2017-06-02 | 2022-07-18 | 후지필름 도야마 케미컬 가부시키가이샤 | 타우병증 예방 또는 치료제 |
| CA3067453C (en) | 2017-06-02 | 2021-11-23 | Fujifilm Toyama Chemical Co., Ltd. | Agent for preventing or treating brain atrophy |
| US11666551B2 (en) | 2017-06-02 | 2023-06-06 | Fujifilm Toyama Chemical Co., Ltd. | Agent for reducing amount of amyloid β protein |
| WO2018221730A1 (ja) | 2017-06-02 | 2018-12-06 | 富山化学工業株式会社 | 脊髄小脳変性症予防または治療剤 |
| US11548878B2 (en) | 2017-10-30 | 2023-01-10 | Fujifilm Toyama Chemical Co., Ltd. | Emopamil binding protein binding agent and use thereof |
| EP3743426A1 (en) * | 2018-01-24 | 2020-12-02 | AC Immune SA | Azacarboline compounds for the detection of tau aggregates |
| EP3743427B1 (en) * | 2018-01-24 | 2022-10-19 | AC Immune SA | Novel method of preparing an imaging compound |
| EP3743423A1 (en) | 2018-01-24 | 2020-12-02 | AC Immune SA | Gamma-carboline compounds for the detection of tau aggregates |
| EP3999182A1 (en) | 2019-07-17 | 2022-05-25 | Arvinas Operations, Inc. | Tau-protein targeting compounds and associated methods of use |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1268771A (en) | 1968-03-15 | 1972-03-29 | Glaxo Lab Ltd | Azacarbazoles |
| WO2008132454A1 (en) * | 2007-04-26 | 2008-11-06 | Ge Healthcare Limited | Carbolines and their use as imaging agents |
| US20110046378A1 (en) * | 2008-02-14 | 2011-02-24 | Siemens Medical Solutions Usa, Inc. | Novel Imaging Agents for Detecting Neurological Dysfunction |
| US8815840B2 (en) * | 2008-12-19 | 2014-08-26 | Bristol-Myers Squibb Company | Carbazole and carboline kinase inhibitors |
| EP2852572B1 (en) * | 2012-05-22 | 2020-04-01 | Eli Lilly and Company | Carboline and carbazole based imaging agents for detecting neurological dysfunction |
| WO2014194169A1 (en) | 2013-05-31 | 2014-12-04 | The General Hospital Corporation | Radiosynthesis of tau radiopharmaceuticals |
| WO2015010263A1 (en) * | 2013-07-24 | 2015-01-29 | Telefonaktiebolaget L M Ericsson(Publ) | Method and apparautus relating to reception of radio signals |
| PT3055308T (pt) * | 2013-10-08 | 2018-01-18 | Hoffmann La Roche | Resumo |
| US10662193B2 (en) * | 2014-01-21 | 2020-05-26 | Ac Immune Sa | Carbazole and carboline compounds for use in the diagnosis, treatment, alleviation or prevention of disorders associated with amyloid or amyloid-like proteins |
| EP3253762B1 (en) * | 2015-02-02 | 2021-05-05 | UCB Biopharma SRL | 9h-pyrrolo-dipyridine derivatives |
-
2016
- 2016-01-29 EP EP16702121.1A patent/EP3253762B1/en active Active
- 2016-01-29 CN CN201680008314.3A patent/CN107207508B/zh active Active
- 2016-01-29 US US15/547,980 patent/US20180022748A1/en not_active Abandoned
- 2016-01-29 KR KR1020177024371A patent/KR102621513B1/ko active Active
- 2016-01-29 DK DK16702121.1T patent/DK3253762T3/da active
- 2016-01-29 MY MYPI2017702668A patent/MY191590A/en unknown
- 2016-01-29 JP JP2017540724A patent/JP6579670B2/ja active Active
- 2016-01-29 WO PCT/EP2016/051993 patent/WO2016124508A1/en not_active Ceased
- 2016-01-29 AU AU2016214537A patent/AU2016214537B2/en active Active
- 2016-01-29 ES ES16702121T patent/ES2875734T3/es active Active
- 2016-01-29 CA CA2973648A patent/CA2973648C/en active Active
- 2016-01-29 MX MX2017009505A patent/MX378155B/es unknown
- 2016-01-29 SG SG11201705727TA patent/SG11201705727TA/en unknown
- 2016-01-29 BR BR112017016311A patent/BR112017016311A2/pt not_active Application Discontinuation
- 2016-01-29 EA EA201791733A patent/EA036518B1/ru not_active IP Right Cessation
-
2017
- 2017-07-10 IL IL253381A patent/IL253381B/en active IP Right Grant
- 2017-07-27 CL CL2017001923A patent/CL2017001923A1/es unknown
-
2020
- 2020-01-22 US US16/749,537 patent/US11312716B2/en active Active
-
2022
- 2022-03-21 US US17/700,075 patent/US12006316B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2973648C (en) | 2023-09-26 |
| DK3253762T3 (da) | 2021-07-19 |
| EP3253762B1 (en) | 2021-05-05 |
| JP6579670B2 (ja) | 2019-09-25 |
| US20220213103A1 (en) | 2022-07-07 |
| IL253381B (en) | 2020-10-29 |
| US20210047326A1 (en) | 2021-02-18 |
| CN107207508A (zh) | 2017-09-26 |
| JP2018503673A (ja) | 2018-02-08 |
| KR102621513B1 (ko) | 2024-01-04 |
| ES2875734T3 (es) | 2021-11-11 |
| WO2016124508A1 (en) | 2016-08-11 |
| CN107207508B (zh) | 2020-02-28 |
| KR20170113607A (ko) | 2017-10-12 |
| MX378155B (es) | 2025-03-10 |
| EP3253762A1 (en) | 2017-12-13 |
| AU2016214537B2 (en) | 2018-05-10 |
| AU2016214537A1 (en) | 2017-08-03 |
| US11312716B2 (en) | 2022-04-26 |
| MX2017009505A (es) | 2017-11-02 |
| BR112017016311A2 (pt) | 2018-03-27 |
| US12006316B2 (en) | 2024-06-11 |
| EA036518B1 (ru) | 2020-11-18 |
| CA2973648A1 (en) | 2016-08-11 |
| IL253381A0 (en) | 2017-09-28 |
| MY191590A (en) | 2022-06-30 |
| US20180022748A1 (en) | 2018-01-25 |
| SG11201705727TA (en) | 2017-08-30 |
| EA201791733A1 (ru) | 2018-01-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2017001923A1 (es) | Derivados de 9h-pirrolo-dipiridina | |
| SV2018005794A (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos | |
| GT201700189A (es) | Derivados de nucleósidos sustituidos útiles como agentes antineoplásicos | |
| CU20180001A7 (es) | Derivados de oxopiridina sustituidos y procesos para su preparación | |
| CL2018000730A1 (es) | Compuestos heterocíclicos y usos de los mismos | |
| ECSP19089214A (es) | Inhibidores de quinasa y usos de los mismos | |
| DOP2017000298A (es) | Reguladores de nrf2 | |
| CL2016001973A1 (es) | Derivados de nucleosido sustituidos con 4' -difluorometilo como inhibidores de la replicación de arn de la influenza. | |
| DOP2015000270A (es) | Potenciador de inhibidores del homólogo de zeste | |
| MX2018003130A (es) | Compuestos de heteroarilo como inhibidores de cinasas asociadas a receptor de interleucina-1 (irak) y usos de los mismos. | |
| CR20170564A (es) | Nuevos derivados hidroxiéster, un proceso para su preparación y composiciones farmacéuticas que los contienen | |
| GT201400144A (es) | Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| CR20180072A (es) | Nuevos compuestos biciclicos como inhibidores de atx | |
| MX2016015565A (es) | Ciertos inhibidores de la proteina quinasa. | |
| CO2019006687A2 (es) | Polimorfos | |
| ECSP18074962A (es) | Derivados de aminotiazol útiles como agentes antivíricos | |
| MX2018002416A (es) | Derivados de 1,7-diaril-1,6-heptadien-3,5-diona, procedimiento para la preparación y uso de los mismos. | |
| MX2017007377A (es) | Compuestos organicos. | |
| MX2017014459A (es) | Compuestos de tioeter como inhibidores de la nitrificacion. | |
| CL2018001493A1 (es) | Nuevos derivados de fenilo | |
| UY38031A (es) | Hidroxiisoxazolinas y derivados de estos | |
| DOP2018000066A (es) | Compuestos útiles para inhibir ror-gamma-t | |
| CL2017000587A1 (es) | Derivados de tetrahidroquinolina como inhibidores de bromodominio | |
| CL2017000151A1 (es) | Derivados de piridona | |
| MX2018013701A (es) | Derivados de piridinilo, composiciones farmaceuticas y sus usos como inhibidores aoc3. |